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month and cost/ OS month gained over control for each treatment, across the 
EU5, were then calculated. Results: Based on total OS, docetaxel consistently 
offered the lowest cost/OS month across the EU5 with a median cost of € 531/ OS 
month. For post-chemotherapy indications, Zytiga had the highest cost/OS month 
(€ 1820-€ 2904) in all countries except Italy, where Xtandi was higher (€ 3620). In 
contrast, for the pre-chemotherapy indications ,Xtandi had the highest cost/OS 
month (€ 1839 - € 4112) across the EU5. When comparing price/OS month gained 
over control, there was significant variation across products. For example, the 
EU5 median cost/OS month were significantly higher for the pre-chemotherapy 
indications for Zytiga and Xtandi (€ 12,869 and € 27,281 respectively) versus their 
post-chemotherapy indications (€ 7136 and € 6252 respectively). Jevtana’s EU5 
median cost of € 11,322, for post-chemotherapy, was comparable to the cost/OS 
month gained over control for the pre-chemotherapy indications of Zytiga and 
Xtandi. ConClusions: Payers do not equally value cost/OS month, as observed 
by the range of costs/OS month across products. Similarly, there is significant 
variation in the price/OS month gained over control, with payers paying signifi-
cantly more for the pre-chemotherapy compared to post-chemotherapy indica-
tions, inferring that payers maybe willing to pay more for treatments earlier in 
the treatment pathway for mCRPC.
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objeCtives: To analyze budget impact and determine cost-effectiveness of differ-
ent strategies of hemostasis during hepatic resection in patients with benign and 
malignant tumors. Methods: A pharmacoeconomic model of application of differ-
ent strategies of hemostasis in target population of patients was created based on 
the data of clinical study by J. Briceño et al. (2010). Two groups of patient (100 persons 
each) were considered: 1st with tachocomb fibrin-coated collagen fleece, and 2nd 
with alternative hemostatic technologies (standard care). The calculation included 
direct costs of pharmacotherapy with different hemostatic strategies, cost of stay 
in hospital, costs of hepatectomy, and costs of blood transfusion. Results: Total 
costs were significantly lower in the group of fibrin-coated collagen fleece compared 
with the group of standard care (8,502,298.53 RUB vs. 9,243,846.02 RUB, respectively). 
Analysis of budget items showed that costs of hospitalization were 3,952,000 RUB 
in tachocomb group, and 5,200,000 RUB in the control group. In addition, the use of 
fibrin-coated collagen fleece reduced the financial costs of blood transfusion nearly 
threefold (456,146.02 RUB and 124,598.53 RUB, respectively). Cost-effectiveness ratio 
defined as a number of patients with no complications after minor or extensive 
hepatic resection was 135,938.91 and 111,872.35 in the standard care group and 
tachocomb group, respectively. ConClusions: Pharmacoeconomic advantages 
were established for the strategy with application of tachocomp fibrin-coated col-
lagen fleece during hepatectomy of patients with for benign and malignant tumors. 
The benefits were connected with lower financial costs and more favorable cost-
effectiveness.
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objeCtives: To compare the cost associated with advanced breast cancer treated 
with vinorelbine oral (VinO) versus IV (VinIV) from the national health services 
perspective in France. Methods: This was an observational, prospective, inter-
national, multicentric study. This analysis focused on French patients who were 
included in the study at the beginning of their 2nd cycle of chemotherapy with 
vinorelbine and categorized in 2 groups depending on whether they are receiving 
VinO or VinIV. In and out-patient resource utilization was collected during two 
cycles. The analysis was conducted according to the recommendations published 
by the Haute Autorité de la Santé. Results are expressed in euros 2014. The economic 
perspective is the one of the Sécurité Sociale. Results: 43 patients received VinO 
and 8 VinIV. No major difference was found between the two groups on the main 
known economics-related confounding factors. Median cost for transportation was 
lower in the VinO than in the VinIV treated patients: 85€ versus 265€ . No major out-
patient cost differences were reported on paramedical care, lab tests, imageries and 
medical visits. However, ambulatory costs (1,125€ vs 129€ ) and other drugs (287€ 
vs 85€ ) were higher for VinO chemotherapy. On the contrary, in-patient cost were 
found higher in VinIV patients (2,699€ versus 1,360€ ). Overall, patients treated with 
VinO (3,122€ ) cost less than VinIV (3,284€ ), resulting in a saving of 81€ per cycle. If 
about 10,000 cycles were to be administered in France, savings related to VinO would 
amount to 0.86m€ . ConClusions: This survey demonstrated that VinO prescribed 
in daily practice is associated with reduced hospitalization in comparison to its 
IV form and decreased cost to the Sécurité Sociale, for the same level of efficacy. 
Policies aimed at reinforcing the use of oral chemotherapy might result in saving 
to National Health Care Services.
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objeCtives: The objective of this study of breast cancer patients enrolled in the 
EMILIA clinical study was to compare costs of treating patients with either ado-
trastuzumab emtansine (T-DM1) or lapatinib plus capecitabine (L+C). Methods: 
All healthcare resource utilization (HCRU) and study drug costs for the EMILIA clini-
objeCtives: To determine the most cost-effective treatment scheme for tran-
sitional cell carcinoma of the urothelial tract (TCCU) in second line through the 
comparison of vinflunine+ best supportive care (BSC) and BSC from a payer per-
spective. Methods: Cost-effectiveness and budget impact analysis were per-
formed. Efficacy data came from phase III clinical trial. The economic perspective 
was the one of the Russian national health system. Results are expressed in RUB, 
year 2015. Sensitivity analysis were conducted to check the robustness of our find-
ings. Results: ICER was calculated: 1 114 504 RUB/18 541 EUR life-year gained (LYG). 
Budget impact analysis revealed that, a treatment with vinflunine+BSC required 
additional costs: 332 944 RUB/5 539 EUR for a 3-cycle treatment course. According 
to the budget impact analysis, shifting from a vinflunine+BSC treatment to BSC 
alone requires additional costs of 241 384 391 RUB/4 015 711 EUR for TCCU patients 
after failure of a prior platinum-containing regimen in Russia for a fulltreatment 
course. ConClusions: Vinflunine+BSC is cost-effective, as ICER does not exceed 
the willingness-to-pay threshold of Russia, which equals 1 481 749 RUB/24 651 EUR. 
And this ICER per LYG is lower than the ones calculated for the other chemothera-
pies used in oncology.
PCN82
PharmaCoeCoNomiC aNalysis of ferriC Carboxymaltose iN PatieNts 
with ColoN CaNCer aND aNemia
Ryazhenov VV1, Gorokhova SG2, Maximkin SA3
1I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 2Research Clinical Center 
of JSC Russian Railways, Moscow, Russia, 3Center for strategic research in healthcare, Moscow, 
Russia
objeCtives: To conduct a budget impact and cost effectiveness analysis of 
ferric carboxymaltose in Russian patients with colon cancer in preoperative 
period. Methods: Based on literature data (Salvadora Delgado et al. 2013, Efficacy 
of Preoperative Administration of Ferric Carboxymaltose in Colon Cancer Patients 
and Anemia) we created a pharmacoeconomic model of intravenous iron therapy 
in patients with colon cancer and anemia. The study included two groups (100 
patients each), treated with ferric carboxymaltose and placebo, respectively. The 
model included costs of medications, hospitalization and transfusions. Results: 
Total costs were 10 679 174 rub. in placebo group and 10 518 707 rub. in ferric car-
boxymaltose group. The costs of blood transfusion were 3.9 times lower in carboxy-
maltose group compared to control (placebo group); hospitalization in this group 
lasted shorter, which reduced costs 1.23 times (4 155 000 rub. and 5 100 000 rub., 
respectively). The role of cost effectiveness ratio in terms of clinical result without 
clinical complications was 132 644,50 for ferric carboxymaltose and 145 294,90 in 
placebo group. ConClusions: The application of ferric carboxymaltose in patients 
with colon cancer is justified by the comparative effectiveness estimated in budget 
impact analysis, and allows reducing costs in healthcare system.
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objeCtives: Non-Hodgkin’s lymphomas (NHLs) account for 90% of all lympho-
mas. Rituximab intravenous (IV) infusion represents a widely used therapeutic 
option against CD20-positive lymphomas. Recently, the therapeutically equivalent 
subcutaneous (SC) formulation was made available. Taking into account that SC 
formulations can result in resource and cost savings compared to IV forms of 
the same medication, this study aims to perform a cost-minimization (CMA) and 
budget-impact analysis (BIA) of introducing and switching to Rituximab SC injec-
tion for the treatment of NHLs in Greece. Methods: A questionnaire-based sur-
vey to a group of clinical practitioners that manage NHL patients formed the basis 
of the analyses. The collected data captured the resources used for the preparation 
and administration of Rituximab SC and/or IV, namely staff times, medications, 
consumables and overheads during patient stay. A CMA compared the costs of 
Rituximab SC versus IV by estimating the total cost/patient over the full course 
of treatment and the BIA estimated the impact of different penetration scenarios 
of the two formulations over a 3-year period. Calculations followed a third party 
payer perspective, according to the health system’s official price lists. Results: 
Results indicated that the SC administration provided a 77% reduction in the 
average time the nurses spent on a patient and a reduction of 90% in the time 
that the infusion chair was occupied. The average administration cost per patient 
over the full course of treatment was 13.627€ and 14.245€ for the SC and the 
IV, respectively. Budget savings for the first year of full implementation of SC 
administration was 618.708€ for a population of 1.000 patients. ConClusions: 
The outcomes suggest that the introduction of Rituximab SC in the treat-
ment of NHL could provide the grounds for efficient resource allocation within 
the hospital setting, as well as increasing maximum capacity to facilitate 
demand.
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objeCtives: There have been several recent product launches for the treatment 
of metastatic castration resistant prostate cancer (mCRPC). The aim of this study 
was to assess the cost of mCRPC treatments across the EU5 (France, Germany, 
Italy, Spain, UK) in relation to overall survival (OS), to determine if payers equally 
value the cost/ OS month for mCRPC treatments. Methods: Median OS (total and 
gain vs control arm) and average treatment duration were extracted from Phase III 
trial data for Zytiga, Xtandi, Jevtana, and docetaxel for each approved indication. 
Launch prices were extracted from publically available sources. The cost/total OS 
